Impact of Pneumococcal Vaccine on Pneumonia in Uganda
Author Information
Author(s): Wanyana Mercy Wendy, Migisha Richard, King Patrick, Bulage Lilian, Kwesiga Benon, Kadobera Daniel, Ario Alex Riolexus, Harris Julie R.
Primary Institution: Uganda National Institute of Public Health
Hypothesis
What is the long-term impact of the 10-valent pneumococcal conjugate vaccine on pneumonia admissions and deaths among children under 5 years in Uganda?
Conclusion
The introduction of the pneumococcal conjugate vaccine in Uganda has led to significant declines in pneumonia admissions and mortality rates among children under 5 years.
Supporting Evidence
- From 2014 to 2021, pneumonia admissions among children under 5 years declined from 31% to 15%.
- Pneumonia mortality rates decreased from 24 to 14 deaths per 100,000 children under 5 years.
- The overall case-fatality rate for pneumonia in children under 5 years dropped from 0.57% to 0.24%.
Takeaway
This study shows that giving a special vaccine to young children in Uganda has helped reduce the number of kids getting very sick from pneumonia and dying from it.
Methodology
The study analyzed secondary data on pneumonia admissions and deaths from the District Health Information System from 2014 to 2021.
Potential Biases
Potential underestimation of pneumonia mortality due to reliance on inpatient data.
Limitations
The study relied on aggregated secondary data, which may not capture all pneumonia cases and deaths, and lacked data before the vaccine's introduction for comparison.
Participant Demographics
Children under 5 years in Uganda.
Statistical Information
P-Value
0.019
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website